Aurealis Therapeutics announces 7.8MCHF financing to advance lead candidate AUP-16 for diabetic foot ulcers under new brand: Aurealis Therapeutics AG
Aurealis Therapeutics, a private biopharmaceutical company developing novel three-in-one combination biologics for chronic non-healing wounds and cancer announced 7.8MCHF funding provided by Swiss and foreign private investors, Finnvera plc, and Business Finland – the Finnish Innovation Funding Agency. The company also confirmed the de-merger and a plan to develop and commercialize the AUP-16 under a […]
